Cargando…
Oral Immunotherapy in Food Allergy: Where Are We Now?
Food allergy (FA) has become more prevalent and problematic in the last 2 decades, and it poses important individual, social, and economic burdens. Besides treating reactions induced by accidental exposure and periodic evaluation for acquiring natural tolerance, the primary management approach is st...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079524/ https://www.ncbi.nlm.nih.gov/pubmed/37021501 http://dx.doi.org/10.4168/aair.2023.15.2.125 |
_version_ | 1785020743000522752 |
---|---|
author | Özdemir, Pınar Gökmirza Sato, Sakura Yanagida, Noriyuki Ebisawa, Motohiro |
author_facet | Özdemir, Pınar Gökmirza Sato, Sakura Yanagida, Noriyuki Ebisawa, Motohiro |
author_sort | Özdemir, Pınar Gökmirza |
collection | PubMed |
description | Food allergy (FA) has become more prevalent and problematic in the last 2 decades, and it poses important individual, social, and economic burdens. Besides treating reactions induced by accidental exposure and periodic evaluation for acquiring natural tolerance, the primary management approach is still allergen avoidance as a global standard. However, an active therapeutic approach that can raise the reaction threshold or accelerate tolerance is needed. This review aimed to provide an overview and the latest evidence of oral immunotherapy (OIT), which has recently been used in the active treatment of FA. FA immunotherapy, particularly OIT, is gaining considerable interest, and substantial effort has been made to integrate this active treatment into clinical practice. Consequently, growing evidence has been obtained regarding the efficacy and safety of OIT, particularly for allergens such as peanuts, eggs, and milk. However, several issues need to be addressed regarding the availability, safety, and long-term effects of this intervention. In this review, we summarize currently available information regarding tolerance-inducing immune mechanisms of OIT, data on efficacy and safety, gaps in current evidence, and ongoing research to develop new therapeutic molecules in order to enhance safety. |
format | Online Article Text |
id | pubmed-10079524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-100795242023-04-08 Oral Immunotherapy in Food Allergy: Where Are We Now? Özdemir, Pınar Gökmirza Sato, Sakura Yanagida, Noriyuki Ebisawa, Motohiro Allergy Asthma Immunol Res Review Food allergy (FA) has become more prevalent and problematic in the last 2 decades, and it poses important individual, social, and economic burdens. Besides treating reactions induced by accidental exposure and periodic evaluation for acquiring natural tolerance, the primary management approach is still allergen avoidance as a global standard. However, an active therapeutic approach that can raise the reaction threshold or accelerate tolerance is needed. This review aimed to provide an overview and the latest evidence of oral immunotherapy (OIT), which has recently been used in the active treatment of FA. FA immunotherapy, particularly OIT, is gaining considerable interest, and substantial effort has been made to integrate this active treatment into clinical practice. Consequently, growing evidence has been obtained regarding the efficacy and safety of OIT, particularly for allergens such as peanuts, eggs, and milk. However, several issues need to be addressed regarding the availability, safety, and long-term effects of this intervention. In this review, we summarize currently available information regarding tolerance-inducing immune mechanisms of OIT, data on efficacy and safety, gaps in current evidence, and ongoing research to develop new therapeutic molecules in order to enhance safety. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2023-03-31 /pmc/articles/PMC10079524/ /pubmed/37021501 http://dx.doi.org/10.4168/aair.2023.15.2.125 Text en Copyright © 2023 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Özdemir, Pınar Gökmirza Sato, Sakura Yanagida, Noriyuki Ebisawa, Motohiro Oral Immunotherapy in Food Allergy: Where Are We Now? |
title | Oral Immunotherapy in Food Allergy: Where Are We Now? |
title_full | Oral Immunotherapy in Food Allergy: Where Are We Now? |
title_fullStr | Oral Immunotherapy in Food Allergy: Where Are We Now? |
title_full_unstemmed | Oral Immunotherapy in Food Allergy: Where Are We Now? |
title_short | Oral Immunotherapy in Food Allergy: Where Are We Now? |
title_sort | oral immunotherapy in food allergy: where are we now? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079524/ https://www.ncbi.nlm.nih.gov/pubmed/37021501 http://dx.doi.org/10.4168/aair.2023.15.2.125 |
work_keys_str_mv | AT ozdemirpınargokmirza oralimmunotherapyinfoodallergywherearewenow AT satosakura oralimmunotherapyinfoodallergywherearewenow AT yanagidanoriyuki oralimmunotherapyinfoodallergywherearewenow AT ebisawamotohiro oralimmunotherapyinfoodallergywherearewenow |